Phase 2 trials of QLS-111 meet endpoints, showing promise for glaucoma and ocular hypertension treatment
Qlaris Bio, Inc announced positive topline results from two Phase 2 clinical trials evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Both trials, Osprey and Apteryx, met all primary and secondary endpoints, demonstrating the potential of QLS-111 to address unmet needs in ophthalmic diseases.
The Osprey study, involving 62 adults, assessed the safety, tolerability, and intraocular pressure (IOP)-lowering effects of QLS-111. The 0.015% concentration of QLS-111, dosed once daily, achieved a significant reduction in IOP, with a mean decrease of 3.7 mmHg from a baseline of 23.0 mmHg.
The Apteryx study focused on patients aged 12 and older who were stable on latanoprost monotherapy. When QLS-111 was added to latanoprost, it produced an additional mean IOP reduction of 3.2 mmHg with once-daily dosing and 3.6 mmHg with twice-daily dosing.
Both studies confirmed that QLS-111 was safe and well-tolerated, with no serious adverse events or clinically significant hyperemia reported. Qlaris Bio will present further details at the Glaucoma 360 New Horizons Forum on February 7th in San Francisco.
Read the full press release here.
Related Content
